MediLOT는 제어 및 데이터 레이어 위에 기계 학습 및 데이터 분석 기능을 통합 한 독창적 인 계층화 된 아키텍처를 갖춘 이중 블록 체인 기반 EHR 생태계이므로 복잡한 애플리케이션을 갖춘 기계 학습 API를 시스템 상단에 구축 할 수 있습니다. / p>
모든 거래를 기록하는 분산 원장 (Hyperledger ++)을 보유함으로써 모든 종업원 환자 데이터는 임상 사용을 위해 허가 된 의료 종사자가 언제든지 검색 할 수 있습니다. 그런 다음 이러한 건강 기록은 환자의 허락하에 다른 기관을 통해 액세스 할 수 있습니다. 예를 들어, 이전에 치료를받지 않은 병원을 방문한 환자는 액세스 권한이 부여 된 의사 또는 임상의가 MediLOT을 통해 전체 건강 기록에 액세스 할 수 있기 때문에 조사를 다시하지 않아도됩니다. 또한 장기 기증, 진료 지침 및 연구와 관련된 차등 동의 선택 사항도 블록 체인에 기록되어 보편적으로 이용할 수 있습니다. 특히, 연구를위한 데이터 사용과 관련된 동의 선택은 세분화 된 방식으로 캡처 할 수 있으므로 연구원은 환자가 자신의 생물학적 물질의 사용을 비롯하여 연구에 사용되는 데이터에 대한 동의 여부와 재사용 여부를 즉각적으로 식별 할 수 있습니다. 필요한 경우 식별이 허용됩니다.
Q1 2019
Q2 2019
Q3 2019
Q1 2020
Q2 2020
Q4 2020
Q2 2021
검증 됨 0%
주의. 확인되지 않은 회원은 실제로 팀원이 아닌 위험이 있습니다.
We believe that MediLOT is one of the exciting upcoming IEO and here are the reasons why:
First of all, the project is formulated and executed by a Singapore-based team with solid experience in medicine, tech and business development. The core members are from the blockchain and healthcare spheres:
- Co-founder Professor Beng Chin Ooi is 1 of the 2 Distinguished Professors and has spent over 30 years at the National University of Singapore's Department of Computer Science
- Co-founder Professor Meihui Zhang is a Professor at the Beijing Institute of Technology and a winner of prestigious China's Young Scholar Thousand Talents Program in 2018
- Co-founder Dr Marcus Tan is an Opthalmologist (Eye Specialist) and a Clinical Lecturer at the National University of Singapore
- CEO Koon Swee Lim has 25 years of senior management experience in healthcare industry, biomedical technology commercialisation and investments
The research done by MediLOT's team of professors has been cited in many reputable publications.
Backed by equity investor SG Innovate, the Singapore Government Venture Capital Fund, MediLot has a monopoly in Singapore, having already partnered with National University Hospital (the largest medical research institution in Singapore). More contracts with other Singapore hospitals will be announced. The team has also secured a foothold in the fast-growing China healthcare market.
Secondly, we like the idea of the project because it has a real use-case with seamless adoption of blockchain in our daily life. In summary, MediLOT is a dual blockchain-based Electronic Health Records platform that allows individual patients to grant healthcare providers, research institutions and pharmaceuticals access to their encrypted medical data by indicating the storage location. This is a highly secure solution which adheres to GDPR and other stringent data privacy regulations. Patients will be incentivized and empowered to permit the usage of their data to facilitate research, such as the research to create new drugs and treatments for cancers.
Thirdly, the token metrics is reasonable while the tokenomics is deflationary. IEO hardcap is $1,500,000 (for 8.5% of total token supply) while the initial circulating supply is $2,168,366. LOT Tokens retained by the MediLOT Platform will be burnt.
Last but not least, Ricky Ng, the founder of Bitsdaq, is one of the advisors, so we will keep an eye on it. Probably it will be an IEO on Bitsdaq Exchange
Medilot has flown under the radar for many of us not focused on developments in Asia but the project has a number of strong points. These include the fact that Medilot is operating in a lucrative sector and has a very much needed use case and is attempting to disrupt an industry that has been using outdated methods for quite some time. On top of this, the project has already developed an MVP and various aspects of the code are available to be verified. Medilot also has a strong core team with partnerships/collaborations with the National University of Singapore, the National University Health System, Singapore, and Chinese hospitals such as the Shandong Province Hospital, the Zhejiang Chinese Medical University Affiliated Jiangnan Hospital, and the Shenzhen Kingcome Hospital.
They have also been backed by SGInnovate, Signum Capital, and two other renowned investors who wish to remain private. which shows they are developing something significant, however, due to the scope of the project Medilot could prove to be a slow burner. There is a long wait until the mainnet with a launch set for Singapore in Q4 2020, and the Asia launch is in Q3 2021. This will leave the LOT token open to pure speculation for quite a while and could even allow the market to grow cold on the project. In addition, in the long term LOT tokens rely on adoption to maintain value and there’s no guarantee this will happen anytime soon. Furthermore, the team do state that in the preliminary stage, organisations who do not wish to stake LOT can deposit fiat which will be treated as a security deposit. This won’t help the token price when the project is getting off the ground, however, the team aim to retain 30% of all LOT Tokens via the platform’s fee structure regarding data sharing. Also LOT tokens held by the Platform will be held to insure against Black Swan events, and may also be burnt by the management as well as locked up by institutions and organisations that choose to stake tokens. The low token sale ratio also increases the importance of the team’s token management; however, with the team getting ready to conduct an IEO, there should be enough positive price action to attract anyone looking for short term returns. Anyone looking to follow the project in the long term should keep an eye on developments and adoption community growth over the next year as the project nears its first mainnet launch.
이 쿠폰은 쿠폰 제공자가 제공 한 정보 및 기타 공개적으로 제공되는 정보를 기반으로합니다. 토큰 판매 또는 교환 이벤트는 ICO 보유자와 전적으로 관련이 없으며 ICOholder는 이에 관여하지 않습니다 (기술 지원 또는 프로모션 포함). ICOholder와 관계가없는 사람들로부터 나열된 토큰 판매는 고객이 전반적인 토큰 부문에서 발생하는 활동을 추적하는 데 도움이되는 경우에만 표시됩니다. 이 정보는 귀하가 의지해야 할 조언에 해당하지 않습니다. 당사 사이트의 내용을 기반으로 한 조치를 취하거나 삼 가기 전에 전문가 또는 전문가의 자문을 구하거나 자신의 실사를 수행해야합니다. 토큰 획득과 관련하여 참가자가 입력 한 조건은 토큰과 ICO 소유자의 발행인이 그러한 토큰의 판매자가 아닙니다. ICO 소유자는 토큰 판매와 관련하여 제 3 자의 진술에 대해 법적 책임이 없으며 계약 위반에 대한 청구는 여기에 열거 된 토큰 발행 기관과 직접 체결해야합니다.
이 토큰 판매 또는 관련 인물의 성격, 적법성 또는 합법성에 대해 우려되는 점이 있으면 info@icoholder.com 에 문의하십시오. 귀하의 우려 사항에 대한 자세한 정보를 제공하십시오.